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reached CZK885,044 (~EUR32,260), with the Cardiohelp device (Maquet, Germany) 
CZK788,432 (~EUR28,738). The cost utility analysis revealed 3,961,970 CZK/QALY 
(~144,413 EUR/QALY) with Cardiohelp, and 4,447,457 CZK/QALY (~162,109 EUR/
QALY) when using Levitronix Centrimag. However, if only patients with CPC 1 were 
included into the analysis, the cost-utility ratio decreased to 834,616 CZK/QALY 
(~30,422 EUR/QALY) and 908,253 CZK/QALY (~33,106 EUR/QALY) for Cardiohelp and 
Levitronix, respectively. ConClusions: Our data indicate that ECPR for refractory 
cardiac arrest might be cost effective despite the high costs per individual patient 
treated with this approach. Larger studies are, however, required to confirm these 
observations.
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objeCtives: Raised heart rate is a risk factor for cardiovascular events and 
death. Heart rate reduction could be an important role in management of chronic 
heart failure. Ivabradine is a new, pure and specific heart rate lower therapy. We 
assessed the cost effectiveness of Ivabradine in CHF with heart rate 75 bpm 
using the perspective of a middle-income country’s public health insurance sys-
tem. Methods: Model-based analysis closely mirrored the SHIFT trial was per-
formed. Micro-simulation method of CHF disease, mortality and hospitalization 
were used to compare Ivabradine plus standard care with standard care only. 
A two state Markov model has been employed to simulate the natural history of 
disease. Costs were estimated from national health insurance research database 
in Taiwan, a single-payer program that offers universal health care coverage. And 
another estimated costs using a medical center in Taiwan with clinical examina-
tion value were performed to validate the accuracy of costs. Incremental cost per 
quality adjusted life year (QALY) gained is used to express the value of Ivabradine 
over a lifetime horizon and 29 months of trial period. Results: The incremen-
tal cost per additional QALY for Ivabradine plus standard care versus standard 
care has been estimated as £14,832 for trial period and £7,634 for lifetime. 
Ivabradine is cost-effective according to NICE threshold. And the result was 
robust in sensitivity analysis. ConClusions: In a middle-income country like 
Taiwan, the use of Ivabradine to treat the eligible CHF patients is likely to be cost 
effectiveness.
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objeCtives: To conduct an economic analysis of the risk assessment of venous 
thromboembolism (VTE) from the perspective of the Spanish National Health 
System with Thrombo inCode versus conventional/standard method used to date 
(Factor V Leiden and Prothrombin G20210A). Methods: An economic model 
was created from the National Health System perspective using a decision tree 
in patients aged 45 with a life expectancy of 81 years. The predictive capacity of 
VTE based on the identification of thrombophilia with Thrombo inCode and of the 
standard method was obtained from two case-control studies (S. PAU and MARTHA) 
conducted on two different populations (1,451 patients in all). Although this is not 
always the case, in this analysis the least favourable situation was assumed for 
Thrombo inCode, with patients identified as suffering from thrombophilia being 
subject to preventive treatment of VTE with warfarin, leading to a reduction in 
the number of VTE events and an increased risk of severe bleeding. The health 
states utilities (quality-adjusted life years, QALY) and costs were obtained from 
the literature and Spanish sources. Results: Based on a price of € 180 for Thrombo 
inCode, this would be the dominant option (more effective and with lower costs than 
the standard method) in both populations. The Monte Carlo probabilistic analyses 
indicate that the dominance would occur in 100% of the simulations in both popu-
lations. The threshold price of Thrombo inCode needed to reach the incremental 
cost-effective ratio (ICER) generally accepted in Spain (€ 30,000 per QALY gained) 
would be between € 3,950 (MARTHA) and € 11,993 (S. PAU). ConClusions: Thrombo 
inCode is a dominant option in assessing the risk of VTE compared to the standard 
method currently used.
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objeCtives: Treatment of varicose veins (VV) has been shown to increase health 
related quality of life. However, the cost-effectiveness of such treatments has been 
uncertain. Indeed there is great regional variation across the UK in how, and if, VV 
are treated. This economic analysis formed part of the NICE clinical guideline on VV, 
with an objective to investigate whether such treatments should be recommended 
across the UK. Methods: An economic analysis was conducted to compare the 
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objeCtives: Non-invasive molecular imaging tests are currently being developed 
to improve individual stroke risk prediction in patients with a recent transient 
ischemic attack (TIA) or minor ischemic stroke. We estimated the minimum per-
formance (i.e., sensitivity and specificity) that a test must have in order to be more 
cost-effective than current clinical practice. Methods: The aim of imaging tests is 
to identify which patients should undergo surgery instead of receiving medicines. 
Decision modelling was used to estimate the minimum performance of a confirma-
tory test that is performed based on the result of an initial duplex ultrasonography. 
The comparators were patient management according to Dutch guidelines and three 
observed clinical practice strategies. Scenario analyses were performed in which the 
sensitivity and specificity were varied to estimate the minimum test performance 
needed to be cost-effective versus the comparators. Results: A perfect confirma-
tory test (100% sensitivity and specificity) with a cost of € 390 for a 60-year-old man 
is cost-effective versus all comparators. Assuming 100% sensitivity, a test must be at 
least 71% specific to be cost-effective versus the Dutch guidelines using a threshold 
of € 30,000/QALY. Similarly, assuming 100% specificity, a test must be at least 52% 
sensitive to be cost-effective. In addition, assuming 90% sensitivity, a test must have 
a specificity of at least 77% to be cost-effective. Moreover, the minimum values of 
sensitivity and specificity needed for a test to be cost-effective are dependent on the 
QALY threshold used. ConClusions: An imaging test that improves risk prediction 
and therefore treatment decisions for patients with a recent TIA or minor ischemic 
stroke has the potential to improve cost-effectiveness by reducing the risk of recur-
rent stroke. However, developers must consider if the minimum test performance 
required to be cost-effective can be achieved; other concerns of payers (e.g. budget 
impact) must also be considered.
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objeCtives: Guidelines suggest only 3-6 months of anticoagulant treatment in 
most venous thromboembolism (VTE) patients due to concerns that the bleeding 
risk with vitamin K antagonists (VKAs) outweighs the reduced risk of VTE recur-
rence in extended treatment. However, non-VKA novel oral anticoagulants (NOACs) 
have been studied recently for extended VTE treatment. Apixaban demonstrated 
superiority to placebo in VTE reduction without increasing risk of major bleeding in 
the AMPLIFY-EXT trial, justifying reassessment of the potential benefit of extending 
treatment. This analysis reports cost effectiveness of lifetime treatment with apixa-
ban versus rivaroxaban, dabigatran, and low-molecular-weight heparin (LMWH)/
KA from the perspective of the UK National Health Service (NHS). Methods: 
A Markov model was developed that includes the following health states: recurrent 
VTE, major bleed, clinically-relevant non-major bleed, chronic thromboembolic 
pulmonary hypertension, and death. Transition rates among health states were 
based upon AMPLIFY and AMPLIFY-EXT clinical trial data, network meta-analyses, 
discontinuation due to clinical events, and UK life tables. Costs were from UK NHS 
Healthcare Resource Group tables and utilities were from published literature. The 
primary outcome of interest was incremental cost per quality adjusted life year 
(QALY) gained. Results: Compared to other anticoagulants, lifetime treatment 
with apixaban was projected to result in fewer bleeds and fewer recurrent VTEs. 
The lower bleeding risk with apixaban led to fewer treatment discontinuations, 
longer time on treatment, and fewer recurrent VTEs. The reduced number of clini-
cal events led to increased QALYs at a nominal cost increase, due primarily to 
longer treatment duration with apixaban. Incremental costs per QALY gained 
were £2,781, £619, and £10,820 for apixaban versus dabigatran, rivaroxaban, and 
LMWH/VKA, respectively. Sensitivity analyses indicated that results were robust 
to a wide range of inputs. ConClusions: Apixaban for lifetime treatment of VTE 
can offer substantial clinical benefits and is a cost-effective alternative to other 
NOACs and LMWH/VKA.
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objeCtives: Extracorporeal life support (ECLS) has been recently introduced as a 
therapeutic option for refractory cardiac arrest (extracorporeal cardiopulmonary 
resuscitation - ECPR). Despite growing evidence demonstrating improved sur-
vival rate with ECPR in refractory cardiac arrest, a number of questions remains 
unanswered and data on cost-effectiveness of this approach are still insuffi-
cient. Methods: Retrospective cost-effectiveness analysis was performed from 
the provider’s perspective. Sixteen patients undergoing ECPR were included into 
the analysis (ECPR group) and the data were compared with 35 subjects with con-
ventional CPR for refractory cardiac arrest (non-ECPR group). Results: In the 
ECPR group seven out of sixteen patients were weaned from ECMO, four of them 
with good neurological outcomes (CPC 1); three patients survived one year with 
CPC 1, one patient survived one year with severe neurological dysfunction (CPC 
3) and one patient with persisting coma (CPC 4). In comparison, in the non-ECPR 
group all patients died within 24 hours. In the ECPR group, when using Levitronix 
Centrimag blood pump (Thoratec, USA), the average annual costs per patient 
